|
SAN
DIEGO, April 18 /PRNewswire-FirstCall/ -- Nanogen,
Inc. (Nasdaq: NGEN), developer of advanced diagnostic
products, announced today that it has entered into
a supply and license agreement with deCode Genetics
to provide a new genomics assay for single nucleotide
polymorphism (SNP) discovery, validation and screening.
The assay incorporates a full range of Nanogen's products,
including the Eclipse(R) Dark Quencher, new DNA linker
technology, modified bases and novel fluorescent dyes,
and allows rapid SNP analysis on a large number of
patient samples.
"The products
and assay that we will provide deCode represent our
comprehensive product menu available from the recent
merger of Nanogen and Epoch Biosciences," said
Howard C. Birndorf, Nanogen's chairman of the board
and CEO. "We are pleased deCode has joined our
roster of licensing partners eager to tap our growing
portfolio of products that enable rapid, high-throughput
genetic analysis."
About Nanogen, Inc.
Nanogen's advanced
diagnostics provide physicians and patients worldwide
with sophisticated information to predict, diagnose
and treat disease. Research and clinical reference
labs use the highly accurate and reliable NanoChip(R)
Molecular Biology Workstation, NanoChip(R) Electronic
Microarray and broad suite of analyte specific reagents
to develop diagnostic tests for variety of diseases.
Nanogen also offers a broad portfolio of patented
nucleic acids chemistries and molecular tools that
accelerate genomic analysis and are compatible with
many systems. The SynX subsidiary offers a line of
point-of-care diagnostic tests and is building expertise
in cardiac related health conditions. Nanogen's ten
years of pioneering research involving nanotechnology
may also have future applications in medical diagnostics,
biowarfare and other industries. For additional information
please visit Nanogen's website at www.nanogen.com.
SOURCE Nanogen, Inc.
CONTACT: Robert Saltmarsh, VP Corporate Development
of Nanogen, Inc.,
+1-858-410-4600, rsaltmarsh@nanogen.com; or Pam Lord,
Media & Investor
Relations, +1-858-527-3494, plord@irpr.com, for Nanogen,
Inc./
/Web site: http://www.nanogen.com /
(NGEN)
|
